These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

292 related articles for article (PubMed ID: 34321846)

  • 41. Mechanistic and therapeutic advances in non-alcoholic fatty liver disease by targeting the gut microbiota.
    Han R; Ma J; Li H
    Front Med; 2018 Dec; 12(6):645-657. PubMed ID: 30178233
    [TBL] [Abstract][Full Text] [Related]  

  • 42. The lipidome in nonalcoholic fatty liver disease: actionable targets.
    Pirola CJ; Sookoian S
    J Lipid Res; 2021; 62():100073. PubMed ID: 33845089
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Impact of exenatide on mitochondrial lipid metabolism in mice with nonalcoholic steatohepatitis.
    Kalavalapalli S; Bril F; Guingab J; Vergara A; Garrett TJ; Sunny NE; Cusi K
    J Endocrinol; 2019 Jun; 241(3):293-305. PubMed ID: 31082799
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Review article: drug-induced liver injury in the context of nonalcoholic fatty liver disease - a physiopathological and clinical integrated view.
    Bessone F; Dirchwolf M; Rodil MA; Razori MV; Roma MG
    Aliment Pharmacol Ther; 2018 Nov; 48(9):892-913. PubMed ID: 30194708
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Sphingolipid metabolism in non-alcoholic fatty liver diseases.
    Régnier M; Polizzi A; Guillou H; Loiseau N
    Biochimie; 2019 Apr; 159():9-22. PubMed ID: 30071259
    [TBL] [Abstract][Full Text] [Related]  

  • 46. [[Current approaches to diagnosing and treating nonalcoholic fatty liver disease].
    Drapkina OM; Deeva TA; Volkova NP; Ivashkin VT
    Ter Arkh; 2014; 86(10):116-23. PubMed ID: 25509904
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Common features of the metabolic syndrome and nonalcoholic fatty liver disease.
    Almeda-Valdes P; Aguilar-Olivos N; Uribe M; Méndez-Sánchez N
    Rev Recent Clin Trials; 2014; 9(3):148-58. PubMed ID: 25514910
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Inhibition of ceramide de novo synthesis reduces liver lipid accumulation in rats with nonalcoholic fatty liver disease.
    Kurek K; Piotrowska DM; Wiesiołek-Kurek P; Łukaszuk B; Chabowski A; Górski J; Zendzian-Piotrowska M
    Liver Int; 2014 Aug; 34(7):1074-83. PubMed ID: 24106929
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Omega-3 fatty acids and nonalcoholic fatty liver disease in adults and children: where do we stand?
    Spooner MH; Jump DB
    Curr Opin Clin Nutr Metab Care; 2019 Mar; 22(2):103-110. PubMed ID: 30601174
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Relationship between adipose tissue dysfunction, vitamin D deficiency and the pathogenesis of non-alcoholic fatty liver disease.
    Cimini FA; Barchetta I; Carotti S; Bertoccini L; Baroni MG; Vespasiani-Gentilucci U; Cavallo MG; Morini S
    World J Gastroenterol; 2017 May; 23(19):3407-3417. PubMed ID: 28596677
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Nonalcoholic fatty liver disease (NAFLD) pathophysiology in obese children and adolescents: update.
    Assunção SNF; Sorte NCB; Alves CD; Mendes PSA; Alves CRB; Silva LR
    Nutr Hosp; 2017 Jun; 34(3):727-730. PubMed ID: 28627213
    [TBL] [Abstract][Full Text] [Related]  

  • 52. The intersection of nonalcoholic fatty liver disease and obesity.
    Woo Baidal JA; Lavine JE
    Sci Transl Med; 2016 Jan; 8(323):323rv1. PubMed ID: 26819197
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Pediatric non-alcoholic fatty liver disease: Recent solutions, unresolved issues, and future research directions.
    Clemente MG; Mandato C; Poeta M; Vajro P
    World J Gastroenterol; 2016 Sep; 22(36):8078-93. PubMed ID: 27688650
    [TBL] [Abstract][Full Text] [Related]  

  • 54. The multiple-hit pathogenesis of non-alcoholic fatty liver disease (NAFLD).
    Buzzetti E; Pinzani M; Tsochatzis EA
    Metabolism; 2016 Aug; 65(8):1038-48. PubMed ID: 26823198
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Non-Alcoholic Fatty Liver Disease.
    Engin A
    Adv Exp Med Biol; 2017; 960():443-467. PubMed ID: 28585211
    [TBL] [Abstract][Full Text] [Related]  

  • 56. APOC3 Protein Is Not a Predisposing Factor for Fat-induced Nonalcoholic Fatty Liver Disease in Mice.
    Cheng X; Yamauchi J; Lee S; Zhang T; Gong Z; Muzumdar R; Qu S; Dong HH
    J Biol Chem; 2017 Mar; 292(9):3692-3705. PubMed ID: 28115523
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Nonalcoholic Fatty Liver Disease: Focus on New Biomarkers and Lifestyle Interventions.
    Notarnicola M; Osella AR; Caruso MG; Pesole PL; Lippolis A; Tutino V; Bonfiglio C; De Nunzio V; Scavo MP; Mirizzi A; Franco I; Lippolis T; D'Alessandro R; Refolo MG; Messa C
    Int J Mol Sci; 2021 Apr; 22(8):. PubMed ID: 33918878
    [TBL] [Abstract][Full Text] [Related]  

  • 58. The Role of Lipid and Lipoprotein Metabolism in Non-Alcoholic Fatty Liver Disease.
    Perla FM; Prelati M; Lavorato M; Visicchio D; Anania C
    Children (Basel); 2017 Jun; 4(6):. PubMed ID: 28587303
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Non-alcoholic fatty liver disease, obesity and the metabolic syndrome.
    Dietrich P; Hellerbrand C
    Best Pract Res Clin Gastroenterol; 2014 Aug; 28(4):637-53. PubMed ID: 25194181
    [TBL] [Abstract][Full Text] [Related]  

  • 60. IGFBP5 modulates lipid metabolism and insulin sensitivity through activating AMPK pathway in non-alcoholic fatty liver disease.
    Xiao Z; Chu Y; Qin W
    Life Sci; 2020 Sep; 256():117997. PubMed ID: 32585242
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.